Glucocorticoid Impact on Interstitial Lung Disease Mortality and Causation

MIMIC-IV data shows ILD patients treated with glucocorticoids had significantly lower survival rates within 14-30 days compared to untreated patients (log-rank P < 0.001). This dataset by Jun Pei, updated May 2026, combines clinical data from MIMIC-IV with Mendelian randomization analysis using GWAS data to explore causal links between glucocorticoid use, lung function, and ILD mortality.

Use Cases

• Assess the association between glucocorticoid use and 30-day mortality in ILD patients based on Kaplan-Meier and Cox model results.
• Investigate causal relationships between glucocorticoids and lung function parameters (FVC, FEV1) using Mendelian randomization analysis.
• Perform stratified analysis on ILD patients with comorbid COPD based on the reported hazard ratios for different glucocorticoid types.

Strengths

• Combines real-world clinical data from MIMIC-IV with genetic causal inference via Mendelian randomization.
• Includes specific statistical results, such as hazard ratios (HR=2.400) and odds ratios (OR=0.957), providing concrete findings.
• Released under a permissive CC-BY-4.0 license for open reuse.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Clinical data is likely from a single source (MIMIC-IV), which may reflect specific patient population biases.

Provenance

Source

Jun Pei via figshare.

Collection Method

Data extracted from the MIMIC-IV database; Mendelian randomization conducted using Genome-Wide Association Studies data.

Freshness

Last updated 2026-05-11 08:00:06; freshness should be verified.

Geography

GWAS data involves individuals of European ancestry; MIMIC-IV geography is unspecified.